← Back to Search

Maestro2 OCT Screening for Glaucoma

N/A

Waitlist Available

Led By Nevin W. El-Nimri, OD, PhD

Research Sponsored by Topcon Corporation

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Subjects 22 years of age or older on the date of data collection (retrospective) or informed consent (prospective)

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 day

Awards & highlights

Study Summary

This trial seeks to create a reliable screening process for medical conditions by gathering data from multiple sources.

Who is the study for?

This trial is for people aged 22 or older with good vision (20/40 or better in each eye) who can understand and sign the consent form. It's not suitable for those unable to undergo eye tests, with certain diseases affecting vision, a history of complex eye surgery, or poor-quality scans.Check my eligibility

What is being tested?

The study aims to develop and validate a new screening process using Maestro2 OCT technology by collecting data from various sites across the U.S., both looking back at past cases and enrolling new participants.See study design

What are the potential side effects?

Since this trial involves non-invasive imaging without medication or surgical intervention, there are no direct side effects associated with Maestro2 OCT. However, discomfort from bright lights during scanning may occur.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 22 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 day

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 day

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 day for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

RNFL and GCL thickness

Trial Design

2Treatment groups

Experimental Treatment

Group I: Pathology (glaucoma) armExperimental Treatment1 Intervention

Group II: Normal armExperimental Treatment1 Intervention

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Topcon CorporationLead Sponsor

11 Previous Clinical Trials

1,370 Total Patients Enrolled

1 Trials studying Glaucoma

125 Patients Enrolled for Glaucoma

Nevin W. El-Nimri, OD, PhDPrincipal InvestigatorTopcon Corporation

Mary Durbin, PhDStudy ChairTopcon Corporation

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Do you have openings for participants in the current clinical trial?

"As reported on clinicaltrials.gov, this medical trial is not currently seeking patients. It was initially posted on 7th November 2023 and most recently updated 13th November 2023. Nevertheless, there are 192 other studies that are presently enrolling participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Screening Protocol

2023. "Screening Protocol". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06135727.

All > Glaucoma